The Trust's Medication Safety Officer (MSO) is responsible for overseeing medicine safety issues and ensuring that any problems are highlighted and communicated within and externally to the Trust. This is facilitated by sending QPAs to key members of staff and managers, through huddles and safety panels, and through this webpage. Copies of QPAs sent are listed below.
MSO is Yasmin Issa
Email: MSO
The Trust Perfect Care Goals for 25/26 have been updated to also include a fifth goal. This goal has been added this year in recognition of the ongoing focus in this area
Our Perfect Care Goals for 25/26 are:
1) Zero moderate / severe harm incidents relating to medicines
2) Zero incorrect medicines administration in non-MCFT settings
3) Zero harm from psychotropic medication
4) Zero harm from rapid tranquilisation
5) Zero incorrect administrations of insulin
MHRA Drug Safety Update February 2025
MHRA Drug Safety update January 2025
MHRA Drug Safety Update December 2024
MHRA Drug Safety Update November 2024
MHRA Drug Safety Update October 2024
MHRA Drug Safety Update September 2024
MHRA Drug Safety Update August 2024
MHRA Drug Safety Update July 2024
MHRA Drug Safety Update June 2024
MHRA Drug Safety Update May 2024
MHRA Drug Safety Update April 2024
MHRA Drug Safety Update March 2024
MHRA Drug Safety Update February 2024
MHRA Drug Safety Update January 2024
MHRA Drug Safety Update December 2023
MHRA Drug Safety Update November 2023
MHRA Drug Safety Update October 2023
MHRA Drug Safety Update September 2023
MHRA Drug Safety Update August 2023
MHRA Drug Safety Update July 2023
MHRA Drug Safety Update June 2023
MHRA Drug Safety Update May 2023
MHRA Drug Safety Update April 2023
MHRA Drug Safety Update March 2023
MHRA Drug Safety Update January 2023
MHRA Drug Safety Update December 2022
MHRA Drug Safety Update November 2022
MHRA Drug Safety Update October 2022
MHRA Drug Safety Update September 2022
MHRA Drug Safety Update August 2022
MHRA Drug Safety Update July 2022
MHRA Drug Safety Update June 2022
MHRA Drug Safety Update May 2022
MHRA Drug Safety Update April 2022
MHRA Drug Safety Update March 2022
MHRA Drug Safety Update Feb 2022
MHRA Drug Safety Update Jan 2022
A National Patient Safety Alert sets out actions healthcare organisations must take to reduce the risk when a new or under recognised patient safety which requires national action is identified.
Quarterly Medicine Alert reports can be found below:
Quarter 4 (Jan-March 2025) Medicines Alert Report
Quarter 3 (Oct-Dec 2024) Medicines Alert Report
Quarter 2(July -Sep 2024) Medicines Alert Report
Quarter 1 (April-June 2023) Medicine Alert Report
Quarter 4 (Jan-March 2023) Medicine Alert Report
Quarter 3 (Oct-Dec 2022) Medicine Alert Report
Quarter 2 (July-September 2022) Medicine Alert Report
Quarter 1 (April-June 2022) Medicine Alert Report
Quarter 4 (Jan-March 2022) Medicine Alert Report
Historically, a number of systems have existed across the Pan Mersey area to collect and share interface problems related to medicines with a view to reducing common problems.
Incidents are fedback to the individual organisation via the trust governance processes.
What are interface issues?
An interface issue is any event that may cause a problem in the management of medicines between different organisations:
- Prescribing not in line with Cheshire and Merseyside APG policies/ formulary
- Inappropriate request for shared care
- Request for an unlicensed medicine
- Request for vaccine outside of guidance
- Inaccurate medication record
- Summary Care Record not up to date
- Illegible or ambiguous information relating to prescribing
- Lack of discharge or reconciliation information
- Lack of referral to NHS Community Services for follow up or ongoing treatment
- Incorrect medication
- Inappropriate changes to medication
- Medicines waste that could be avoided
- Incomplete medication - items unknowingly omitted
- Insufficient medication - items knowingly owed
The issue must first be highlighted with the relevant organisation and any appropriate action required to maintain safe ongoing patient treatment should be dealt with at the time. Any applicable internal incident policies should also be followed.
Interface incidents for St Helens CCG should be reported using the Interface incident form for St Helens CCG
The MSAT was developed to improve the management of medicines related risk to patients. It is intended to provide commissioners with a systematic way of identifying and analysing emerging medicines safety issues and engage with providers to reduce medicines related harm.
It includes useful advice for healthcare professionals on high risk medicines.
This guidance is applicable to former Mid Mersey sites - this is yet to be aligned with similiar existing MCFT guidance.
RADAR Guidance / Reporting / Reflective Analysis
The Medicines and Healthcare Products Regulatory Agency (MHRA) ensures the safety and efficacy of medicinal products and devices and communicates any issues.